Market Context — Why This Technology, Why Now

The pharmaceutical industry is rapidly shifting towards precision medicine and advanced nucleic acid therapeutics, driven by increasing understanding of genetic drivers of disease and a demand for more effective, less toxic treatments. Regulatory bodies are also encouraging novel approaches for unmet medical needs in oncology. This technology aligns perfectly with these trends, offering a targeted solution for hematopoietic tumors that could capture a significant share of the expanding global oncology market by improving patient outcomes and reducing healthcare burdens.

Key Competitive Advantages
01

Achieves high target specificity by precisely controlling the KRAS oncogene network, minimizing impact on healthy cells.

02

Secures early market differentiation by demonstrating high technical uniqueness with only 2 prior art documents.

03

Establishes a long-term business foundation with ~18.1 years of remaining patent life until May 17, 2044.

Market Opportunity
Hematopoietic Tumor Therapeutics Market
$1.5B–$2.5B globally (AI est.)
Strong demand for innovative new drugs is driven by the need to address challenges with existing treatments and improve patient quality of life.
Oncology pharmaceutical companies Biotech firms specializing in hematology Contract research organizations (CROs) for clinical trials
Nucleic Acid Therapeutics Market
$20B–$30B globally (AI est.)
Expectations for next-generation pharmaceuticals are high, with technological advancements expanding the range of applicable diseases.
Large pharmaceutical companies with nucleic acid platforms Gene therapy developers Specialized drug delivery technology companies
Personalized Medicine Sector
$6.5B–$10B globally (AI est.)
The expansion of precision medicine based on genetic information emphasizes providing optimal treatment methods tailored to each patient.
Diagnostic companies developing companion diagnostics Biotech firms focused on genomic medicine Healthcare providers offering advanced oncology services
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a broad scope of 14 claims, establishing patentability through precise amendments and arguments against examiner rejections. Its novelty and inventiveness were clearly recognized, resulting in a robust and stable right with low invalidation risk, maintained until 2044.

Competitive White Space

This patent focuses on KRAS-network-controlled nucleic acid delivery for hematopoietic tumors. Future IP could explore delivery systems for other oncogenes or tumor types, or novel combination therapies with existing immunotherapies, without direct conflict.

Economic Impact
~$10M/year estimated economic impact per facility (AI est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Assuming a new drug's annual sales in the hematopoietic tumor treatment market, this technology could achieve a 5% share in the initial phase, leading to ~$16.5M (AI est.) in sales contribution (market size ~$350M (AI est.) × 5%). Including economic benefits from reduced switching costs and improved treatment efficacy over existing drugs, an annual economic impact of over ~$10M (AI est.) is expected.

Speed to Market
3× faster than in-house development
Basic research by a national R&D agency is complete, establishing the technical basis that specific nucleic acid analog and miRNA combinations are effective for hematopoietic tumors. Its novelty has been recognized during the patent examination process, and essential basic data for transitioning to clinical development is prepared. This significantly shortens the timeline compared to starting R&D from scratch, enabling earlier market entry.
Competitive Positioning

X: Therapeutic Target Specificity
Y: Side Effect Risk Reduction

Business Models & Applications
🤝 Technology Licensing
Accelerate clinical development and commercialization by licensing this technology to pharmaceutical manufacturers. Licensees could contribute to a broad patient base while managing development costs.
🔬 Collaborative R&D
Strengthen collaboration with the national R&D agency to promote joint research and development programs, accelerating clinical application. Share knowledge and resources for efficient development.
🧪 Companion Diagnostic Development
Develop companion diagnostics combined with markers that evaluate KRAS network activity. This could identify optimal patients for this therapy, maximizing treatment efficacy.
Adjacent Application Opportunities
🧬 Gene Therapy
Application to Refractory Solid Tumor Treatment
By applying the technology to control oncogene networks beyond KRAS, it could contribute to developing new therapies for refractory solid tumors like pancreatic or lung cancer, not just hematopoietic tumors. Leveraging the versatility of nucleic acid delivery, it aims for broad cancer type applicability, potentially addressing a global market of ~$100B+ for these difficult-to-treat cancers.
🛡️ Immunotherapy
Immune Cell Function Enhancement and Combination Therapy
Delivering specific miRNAs to modulate immune cell activity could enable combination therapies with existing immunotherapies, such as immune checkpoint inhibitors. This could enhance treatment efficacy and overcome resistance, potentially improving response rates by 20-30% in certain patient populations and offering new value to the ~$50B global immunotherapy market.
🔬 Regenerative Medicine
Stem Cell Differentiation and Proliferation Control
Delivering specific miRNAs to precisely control stem cell differentiation and proliferation could explore applications as a cell manipulation technology in regenerative medicine. Its deployment in cell therapy and tissue regeneration could address new medical needs, potentially impacting a ~$20B global market for advanced cell therapies.
Integration Roadmap — Estimated 60-Month Deployment
Technology Evaluation & Preclinical Research
Duration: 9 months
Conduct internal validation of basic data, evaluate efficacy and safety using animal models, and perform toxicity studies to assess clinical development potential.
Clinical Development Planning & IND Preparation
Duration: 15 months
Develop clinical trial protocols, consult with regulatory authorities, and prepare for investigational drug manufacturing. Compile necessary documents for Investigational New Drug (IND) application.
Clinical Trials & Commercialization Planning
Duration: 36 months
Initiate Phase I clinical trials to confirm human safety and pharmacokinetics. Concurrently, optimize manufacturing processes and formulate commercialization strategies for market launch.
Technical Feasibility
This technology is based on the electrostatic association structure of specific nucleic acid analogs and miRNAs, demonstrating high compatibility with existing nucleic acid drug development platforms and drug delivery systems. The detailed composition is specified in the patent claims, and its manufacturing process is deemed achievable by applying existing biopharmaceutical manufacturing technologies. As no significant new capital investment is required and existing resources can be effectively utilized, the technical barrier to adoption is considered relatively low.
Success Scenario
Implementing this technology could offer a new, highly targeted treatment option with fewer side effects for patient groups currently not achieving sufficient results with existing hematopoietic tumor therapies. This is expected to improve patient quality of life and treatment outcomes, establishing a competitive advantage for the adopting company in the market. Particularly, a precision medicine approach for patients with KRAS mutations could maximize therapeutic efficacy.
Patent Record
APPLICATION NO.
特願2025-515487
REGISTRATION NO.
7725042
FILING DATE
2024/05/17
GRANT DATE
2025/08/08
EXPIRATION DATE
2044/05/17
PATENT HOLDER
国立研究開発法人科学技術振興機構
Examination History
2025年03月12日
早期審査に関する事情説明書
2025年03月12日
手続補正書（自発・内容）
2025年03月12日
出願審査請求書
2025年03月27日
手続補正書（自発・内容）
2025年05月07日
早期審査に関する通知書
2025年05月13日
拒絶理由通知書
2025年07月11日
意見書
2025年07月11日
手続補正書（自発・内容）
2025年07月29日
特許査定